We sought to determine racial and ethnic differences in perceptions (quality of communication, expectations, and concerns) of germline or somatic DNA sequencing (genomic profiling). Patients with prostate, urothelial, or kidney cancer were surveyed using a questionnaire that assessed previous experience, beliefs, expectations, and concerns regarding genomic profiling.
Descriptive statistics and chi-square tests were used to identify factors associated with patients' perceptions of genomic profiling. A total of 150 consecutive patients were enrolled. The majority were male (74%) with a mean age of 68 years old. Most patients underwent somatic testing (54%), 24% undertook germline testing, and 21% undertook both tests. Significant differences were found across racial and/or ethnicity concerning factors that could have influenced patients' decision to pursue genomic profiling, including ability to guide the type of treatment (White: 54.1% vs. other ethnic groups: 43.9%, p = 0.04) and potential to improve treatment response (White: 10.1% vs. other ethnic groups: 22.0%, p = 0.04). Other ethnic group of patients were more concerned about learning that the cancer was less treatable or aggressive (43.8% vs. 27.7%, p = 0.01) and anxious about what would be learnt from genomic profiling (34.4% vs. 21.3, p = 0.01) as compared to White patients. Our findings reinforce the importance of developing culturally tailored education to help patients participate actively in decisions about genomic profiling.
Journal of genetic counseling. 2023 Sep 12 [Epub ahead of print]
Cristiane Decat Bergerot, Errol J Philip, Jasnoor Malhotra, Paulo Gustavo Bergerot, Daniela V Castro, Ameish Govindarajan, Sabrina Salgia, Meghan Salgia, Nicholas Salgia, JoAnn Hsu, Luis Meza, Zeynep B Zengin, Sandy Liu, Alex Chehrazi-Raffle, Abhishek Tripathi, Tanya Dorff, Sumanta Pal
Oncoclinicas, Brasília, Brazil., University of California San Francisco, San Francisco, California, USA., Saint Louis University School of Medicine, St. Louis, Missouri, USA., Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Western University of Health Sciences, Pomona, California, USA., University of Miami School of Medicine, Miami, Florida, USA., Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA., Department of Medical Oncology, City of Hope Orange County Medical Center, Irvine, California, USA.